http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#Head http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#assertion http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#provenance http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#pubinfo http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#assertion http://purl.obolibrary.org/obo/DOID_5419 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_5419 http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01267 http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association http://www.w3.org/2000/01/rdf-schema#label paliperidone is an atypical antipsychotic agent indicated for treatment of schizophrenia 1 1 adults efficacy was established in three 6 week trials and one maintenance trial 14 1 adolescents ages 12 to 17 efficacy was established in one 6 week trial 14 1 treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and or antidepressants 1 2 efficacy was established in two 6 week trials in adult patients 14 2 paliperidone extended release tablets are indicated for the treatment of schizophrenia see clinical studies 14 1 the efficacy of paliperidone in schizophrenia was established in three 6 week trials in adults and one 6 week trial in adolescents as well as one maintenance trial in adults paliperidone extended release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and or antidepressant therapy see clinical studies 14 2 the efficacy of paliperidone in schizoaffective disorder was established in two 6 week trials in adults http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01267 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#provenance http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#pubinfo http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#sig http://purl.org/nanopub/x/hasSignature St6bopRU4x+cvb2RtyVkzLXkLtFRToqNq4sP5L193HA0UF1OZnz+xyzWQDyS97DCrxU+OMcEkl78CcU4bhRiCltWyV/+mK46xiGLAEj0bTlQ642uvtyokxLOoGHuyohLlm2aD+y8vb8M+j/CCmF7IA0gIpjbvhYZO5Qc4X7PRa8= http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg http://purl.org/dc/terms/created 2021-06-27T20:38:29.445+02:00 http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAS58vy1cAZNlnmngw0-gjvhtMXtf2CbshN_Lk_tih3bg https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs